Safety and Effectiveness of Triple Antiretroviral Drug Strategies for Prevention of Mother to Child HIV Transmission (R01)

Funding Opportunity RFA-HD-14-027 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) issued by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institutes of Health (NIH) invites applications to evaluate the safety and effectiveness of implementation of triple antiretroviral drug strategies for prevention of mother to child HIV transmission in resource-constrained settings - either an approach in which antiretroviral drugs stop after breastfeeding cessation in women who don't require therapy for their own health (termed by the World Health Organization "Option B') or a strategy in which life-long antiretroviral therapy is started in all pregnant women regardless of immune or clinical status (sometimes referred to as "Option B+").
Source: NIH Funding Opportunities (Notices, PA, RFA) - Category: Research Source Type: funding